NCT03537274View on ClinicalTrials.gov

Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

1,224

Participants

Timeline

Start Date

August 5, 1997

Primary Completion Date

July 23, 1999

Study Completion Date

July 23, 1999

Conditions
Hepatitis C
Interventions
BIOLOGICAL

PEG-Intron

PEG-Intron is administered QW for 48 weeks by SC injection at 0.5, 1.0, and 1.5 mg/kg body weight. Body weight obtained at the baseline visit is used to calculate dosing.

BIOLOGICAL

Interferon Alfa-2B

Interferon alfa-2b is administered TIW for 48 weeks by SC injection at 3 MIU regardless of participant body weight.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03537274 - Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016) | Biotech Hunter | Biotech Hunter